Search
Bayer HealthCare Links
Clinical trials
Information about clinical studies is available at database of
News
-
2013-06-12 | Worldnews
Bayer HealthCare supports diabetes projects in the Middle East, North Africa and Europe
2013-06-12 | Worldnews
Bayer HealthCare supports diabetes projects in the Middle East, North Africa and Europe
Bayer HealthCare supports local projects under the “Excellence across Borders” program in order to improve care of people with diabetes. Among the projects is a Diabetic School Awareness Program in the Kingdom of Saudi Arabia, which is planned to start in autumn this year. more
-
2013-06-06 | Worldnews
Positive Phase 3 Results for VEGF Trap-Eye (Intravitreal Aflibercept) in Myopic Choroidal Neovascularization (mCNV)
2013-06-06 | Worldnews
Positive Phase 3 Results for VEGF Trap-Eye (Intravitreal Aflibercept) in Myopic Choroidal Neovascularization (mCNV)
Bayer HealthCare announced today positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) from the Phase 3 MYRROR study in myopic choroidal neovascularization (mCNV). more
-
2013-06-05 | Worldnews
Bayer acquires majority interest in Conceptus
2013-06-05 | Worldnews
Bayer acquires majority interest in Conceptus
The Bayer Group has successfully completed its tender offer for the outstanding shares of Conceptus, Inc., Mountain View, California (NASDAQ:CPTS). more
-
2013-06-02 | Cancer
Positive Phase III Data on Sorafenib Show Significant Improvement in Progression-Free Survival Time in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
2013-06-02 | Cancer
Positive Phase III Data on Sorafenib Show Significant Improvement in Progression-Free Survival Time in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Currently there are no approved therapies specifically for radioactive iodine refractory differentiated thyroid cancer / Sorafenib (Nexavar®) significantly extended progression-free survival; median progression-free survival of 10.8 months, compared to 5.8 months with placebo / Results from pivotal Phase III DECISION trial presented in plenary session at Annual Meeting of the American Society of Clinical Oncology more
-
2013-05-30 | Worldnews
Bayer European Regulatory update on Diane-35
2013-05-30 | Worldnews
Bayer European Regulatory update on Diane-35
Bayer HealthCare Pharmaceuticals welcomes the position of the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) of the European Medicines Agency (EMA) that the benefits of Diane-35 outweigh the risks for the treatment of moderate to severe acne related to androgen sensitivity and/or hirsutism (excessive unwanted growth of hair in women) in women of reproductive age. more





